| 臺大學術典藏 |
2022-06-10T06:11:00Z |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; O��Donoghue J.; Beylergil V.; Ruan S.; Pandit-Taskar N.; Gansukh B.; Lyashchenko S.K.; Ma J.; Wan P.; Shao Y.-Y.; ZHONG-ZHE LIN; Frenette C.; O��Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; Cheng A.-L.; Carrasquilo J.A. |
| 臺大學術典藏 |
2021-08-31T06:29:38Z |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; O��Donoghue J.; Beylergil V.; Ruan S.; Pandit-Taskar N.; Gansukh B.; Lyashchenko S.K.; Ma J.; Wan P.; Shao Y.-Y.; Lin Z.-Z.; Frenette C.; O��Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; ANN-LII CHENG; Carrasquilo J.A. |
| 臺大學術典藏 |
2021-08-11T03:46:39Z |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; O��Donoghue J.; Beylergil V.; Ruan S.; Pandit-Taskar N.; Gansukh B.; Lyashchenko S.K.; Ma J.; Wan P.; Shao Y.-Y.; ZHONG-ZHE LIN; Frenette C.; O��Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; Cheng A.-L.; Carrasquilo J.A. |
| 臺大學術典藏 |
2020-04-10T12:15:59Z |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Chen Y.-C.; Ohishi N.; O’Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Frenette C.; Lin Z.-Z.; YU-YUN SHAO; Wan P.; Ma J.; Lyashchenko S.K.; Gansukh B.; Pandit-Taskar N.; Ruan S.; Beylergil V.; O’Donoghue J.; Abou-Alfa G.K.;Yen C.-J.;Hsu C.-H.;O’Donoghue J.;Beylergil V.;Ruan S.;Pandit-Taskar N.;Gansukh B.;Lyashchenko S.K.;Ma J.;Wan P.;Yu-Yun Shao;Lin Z.-Z.;Frenette C.;O’Neil B.;Schwartz L.;Smith-Jones P.M.;Ohtomo T.;Tanaka T.;Morikawa H.;Maki Y.;Ohishi N.;Chen Y.-C.;Agajanov T.;Boisserie F.;Di Laurenzio L.;Lee R.;Larson S.M.;Cheng A.-L.;Carrasquilo J.A.; Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; Cheng A.-L.; Carrasquilo J.A. |
| 臺大學術典藏 |
2020-04-10T12:15:59Z |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Chen Y.-C.; Ohishi N.; O’Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Frenette C.; Lin Z.-Z.; YU-YUN SHAO; Wan P.; Ma J.; Lyashchenko S.K.; Gansukh B.; Pandit-Taskar N.; Ruan S.; Beylergil V.; O’Donoghue J.; Abou-Alfa G.K.;Yen C.-J.;Hsu C.-H.;O’Donoghue J.;Beylergil V.;Ruan S.;Pandit-Taskar N.;Gansukh B.;Lyashchenko S.K.;Ma J.;Wan P.;Yu-Yun Shao;Lin Z.-Z.;Frenette C.;O’Neil B.;Schwartz L.;Smith-Jones P.M.;Ohtomo T.;Tanaka T.;Morikawa H.;Maki Y.;Ohishi N.;Chen Y.-C.;Agajanov T.;Boisserie F.;Di Laurenzio L.;Lee R.;Larson S.M.;Cheng A.-L.;Carrasquilo J.A.; Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; Cheng A.-L.; Carrasquilo J.A. |
| 臺大學術典藏 |
2017 |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Di Laurenzio L.; Lee R.; Larson S.M.; Cheng A.-L.; Carrasquilo J.A.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Morikawa H.; Maki Y.; Tanaka T.; Ohtomo T.; Schwartz L.; Smith-Jones P.M.; Frenette C.; O’Neil B.; Shao Y.-Y.; Wan P.; Ma J.; Gansukh B.; Lyashchenko S.K.; Pandit-Taskar N.; Ruan S.; Beylergil V.; O’Donoghue J.; Yen C.-J.; CHIH-HUNG HSU; Abou-Alfa G.K.; Abou-Alfa G.K.;Yen C.-J.;Chih-Hung Hsu;O’Donoghue J.;Beylergil V.;Ruan S.;Pandit-Taskar N.;Gansukh B.;Lyashchenko S.K.;Ma J.;Wan P.;Shao Y.-Y.;Lin Z.-Z.;Frenette C.;O’Neil B.;Schwartz L.;Smith-Jones P.M.;Ohtomo T.;Tanaka T.;Morikawa H.;Maki Y.;Ohishi N.;Chen Y.-C.;Agajanov T.;Boisserie F.;Di Laurenzio L.;Lee R.;Larson S.M.;Cheng A.-L.;Carrasquilo J.A.; Lin Z.-Z. |
| 臺大學術典藏 |
2017 |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Di Laurenzio L.; Lee R.; Larson S.M.; Cheng A.-L.; Carrasquilo J.A.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Morikawa H.; Maki Y.; Tanaka T.; Ohtomo T.; Schwartz L.; Smith-Jones P.M.; Frenette C.; O’Neil B.; Shao Y.-Y.; Wan P.; Ma J.; Gansukh B.; Lyashchenko S.K.; Pandit-Taskar N.; Ruan S.; Beylergil V.; O’Donoghue J.; Yen C.-J.; CHIH-HUNG HSU; Abou-Alfa G.K.; Abou-Alfa G.K.;Yen C.-J.;Chih-Hung Hsu;O’Donoghue J.;Beylergil V.;Ruan S.;Pandit-Taskar N.;Gansukh B.;Lyashchenko S.K.;Ma J.;Wan P.;Shao Y.-Y.;Lin Z.-Z.;Frenette C.;O’Neil B.;Schwartz L.;Smith-Jones P.M.;Ohtomo T.;Tanaka T.;Morikawa H.;Maki Y.;Ohishi N.;Chen Y.-C.;Agajanov T.;Boisserie F.;Di Laurenzio L.;Lee R.;Larson S.M.;Cheng A.-L.;Carrasquilo J.A.; Lin Z.-Z. |
| 國立成功大學 |
2017 |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Abou-Alfa, G.K.;Yen, C.-J.;Hsu, C.-H.;O’Donoghue, J.;Beylergil, V.;Ruan, S.;Pandit-Taskar, N.;Gansukh, B.;Lyashchenko, S.K.;Ma, J.;Wan, P.;Shao, Y.-Y.;Lin, Z.-Z.;Frenette, C.;O’Neil, B.;Schwartz, L.;Smith-Jones, P.M.;Ohtomo, T.;Tanaka, Tanaka T.;Morikawa, H.;Maki, Y.;Ohishi, N.;Chen, Y.-C.;Agajanov, T.;Boisserie, F.;Di, Laurenzio L.;Lee, R.;Larson, S.M.;Cheng, A.-L.;Carrasquilo, J.A. |
